David Arkowitz
Chief Financial Officer at Seres Therapeutics, Inc. (MCRB)
David Arkowitz has filed 18 insider reports with the SEC since March 2021, as director at iBio, Inc. (IBIO), director at Kineta, Inc./de (KA) and chief Financial Officer at Seres Therapeutics, Inc. (MCRB) and at 3 more companies. David Arkowitz made no open-market purchases or sales in the last 12 months. The latest filing, on November 24, 2025, reports grant or award at iBio, Inc. (IBIO).
- Filings
- 18
- Companies
- 6
- Bought on market
- $50K
- Sold on market
- $25.9K
Companies where David Arkowitz is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Directorsince November 2024 | 18,382 | $50K | $2.72 | $0.801-71% | Nov 24, 2025 | ||
| Director | Sep 5, 2024 | ||||||
| Chief Financial Officer | 182,442 | $9,743 | $1.33 | Feb 17, 2024 | |||
| Director | Apr 14, 2023 | ||||||
| Director | 0 | Mar 9, 2023 | |||||
| Officer | 220,719 | $16.1K | $23.4227 | May 12, 2021 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record. Price now: the latest daily close, against the average buy price.
Every filing
- Nov 20, 2025IBIOSEC Form 4 filed by Director Arkowitz DavidForm 4Grant or award
- Jan 10, 2025+$50KIBIODirector Arkowitz David bought $49,999 worth of shares (18,382 units at $2.72)Form 4Open-market purchase
- Nov 21, 2024IBIOSEC Form 4 filed by Director Arkowitz DavidForm 4Grant or award
- Nov 21, 2024IBIODavid Arkowitz became an insiderForm 3New insider
- Sep 4, 2024KASEC Form 4 filed by Director Arkowitz DavidForm 4Grant or award
- Feb 16, 2024-$4,254MCRBArkowitz David converted options into 10,625 shares and sold $4,254 worth of shares (3,939 units at $1.08), increasing direct ownership by 4% to 182,442 unitsForm 4Grant or awardExercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Oct 30, 2023-$5,489MCRBArkowitz David converted options into 13,209 shares and sold $5,489 worth of shares (4,066 units at $1.35), increasing direct ownership by 5% to 175,756 unitsForm 4Grant or awardExercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Apr 27, 2023MCRBSEC Form 4 filed by Arkowitz DavidForm 4Grant or award
- Apr 12, 2023YMTXSEC Form 4 filed by Arkowitz DavidForm 4Grant or award
- Mar 8, 2023FSTXSEC Form 4: Arkowitz David closing all direct ownership in the company (for withholding tax)Form 4Sale back to the companyOther acquisition or dispositionTender of shares in a change of control
- Feb 3, 2023MCRBSEC Form 4 filed by Arkowitz DavidForm 4Grant or award
- Oct 27, 2022MCRBSEC Form 4: Arkowitz David converted options into 5,000 shares and was granted 42,500 shares, increasing direct ownership by 73% to 112,992 unitsForm 4Grant or awardExercise or conversion of a derivative
- Jul 5, 2022MCRBSEC Form 4: Arkowitz David was granted 63,492 shares, increasing direct ownership by 3,175% to 65,492 unitsForm 4Grant or award
- Jun 17, 2022FSTXSEC Form 4 filed by Arkowitz DavidForm 4Grant or award
- Feb 4, 2022MCRBSEC Form 4 filed by Arkowitz DavidForm 4Grant or award
- Jun 1, 2021MCRBSEC Form 4 filed by Arkowitz DavidForm 4Grant or award
- May 10, 2021-$16.1KFLXNSEC Form 4: Arkowitz David sold $16,116 worth of Common Stock (2,229 units at $7.23), decreasing direct ownership by 1.00% to 220,719 units to satisfy withholding taxForm 4Open-market sale
- Mar 1, 2021FLXNSEC Form 4: David Arkowitz was granted 71,900 units of Common Stock, increasing ownership by 48% to 222,948 unitsForm 4Grant or award
Also sits on boards with
Officers and directors who share two or more companies with David Arkowitz.
- Marion R Foote2 shared: KA, YMTX
- Shawn Iadonato2 shared: KA, YMTX
- Richard Peters2 shared: KA, YMTX
- Kimberlee C Drapkin2 shared: KA, YMTX
- Scott J. Dylla2 shared: KA, YMTX
- Raymond J. Bartoszek2 shared: KA, YMTX
- Craig W. Philips2 shared: KA, YMTX
- Keith Baker2 shared: KA, YMTX
- Thierry Guillaudeux2 shared: KA, YMTX
Compare David Arkowitz with
- David Arkowitz vs Marion R Foote2 shared
- David Arkowitz vs Shawn Iadonato2 shared
- David Arkowitz vs Richard Peters2 shared
- David Arkowitz vs Kimberlee C Drapkin2 shared
- David Arkowitz vs Scott J. Dylla2 shared
- David Arkowitz vs Raymond J. Bartoszek2 shared
Other insiders at the same companies
- Matthew R HennMCRB
- Kelly BradyMCRB
- Thomas DesRosierMCRB
- Eric D. ShaffMCRB
- Molly CarrIBIO
- Willard H DereMCRB
- Dennis A AusielloMCRB
- Richard N KenderMCRB
- Kurt GravesMCRB
- Marella ThorellMCRB
- Robert L. RosielloMCRB
- Claire FraserMCRB
- Stephen BerensonMCRB
- Elizabeth StonerIBIO
- Marc BanjakIBIO
- Felipe DuranIBIO
Questions about David Arkowitz
- What is David Arkowitz's role at Seres Therapeutics, Inc.?
- David Arkowitz reports to the SEC as chief Financial Officer at Seres Therapeutics, Inc. (MCRB), according to the latest filing on February 17, 2024. David Arkowitz has also filed as director at iBio, Inc. (IBIO), director at Kineta, Inc./de (KA), director at Kineta, Inc./de (YMTX) and director at F-star Therapeutics, Inc. (FSTX).
- How many shares does David Arkowitz own?
- After the latest filing that states it, David Arkowitz directly owned 18,382 shares of iBio, Inc. (IBIO), 182,442 shares of Seres Therapeutics, Inc. (MCRB) and 220,719 shares of Flexion Therapeutics Inc (FLXN). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has David Arkowitz bought or sold stock recently?
- The most recent open-market purchase was on January 10, 2025: bought 18,382 shares of iBio, Inc. (IBIO) for $50K at an average of $2.72. The most recent open-market sale was on February 16, 2024: sold 3,939 shares of Seres Therapeutics, Inc. (MCRB) for $4,254 at an average of $1.08.
- How do I get alerts when David Arkowitz files?
- Follow David Arkowitz on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by David Arkowitz (SEC CIK 0001296999). Totals count each trade once, skipping amendments whose original is on file, from Mar 3, 2021 on. View on SEC EDGAR · Get this as JSON